SynthesisPloS one2013
Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the elderly: a meta-analysis.
Synthesis in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 6 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- The role of temozolomide as adjuvant therapy in glioblastoma management: a systematic review and meta-analysis.BMC cancer · 2025Pooled it
- Optimal adjuvant therapy in elderly glioblastoma: results from a systematic review and network meta-analysis.Journal of neuro-oncology · 2020Pooled it
- Management of elderly patients with glioblastoma-multiforme-a systematic review.The British journal of radiology · 2018Pooled it
- Pooled it
- The predictive but not prognostic value of MGMT promoter methylation status in elderly glioblastoma patients: a meta-analysis.PloS one · 2014Pooled it
- A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients.Journal of neuro-oncology · 2014Pooled it
- Outcome of treatment of recurrent glioblastoma multiforme in elderly and/or frail patients.Journal of neuro-oncology · 2016Trial
- Management of glioblastoma in elderly patients: A review of the literature.Clinical and translational radiation oncology · 2024Review
- Genome-wide DNA methylation analysis identifies potent CpG signature for temzolomide response in non-G-CIMP glioblastomas with unmethylated MGMT promoter: MGMT-dependent roles of GPR81.CNS neuroscience & therapeutics · 2024Article
- A Novel Pseudogene Methylation Signature to Predict Temozolomide Outcome in Non-G-CIMP Glioblastomas.Journal of oncology · 2022Article
- Surgical strategies for older patients with glioblastoma.Journal of neuro-oncology · 2021Article
- Exosomal noncoding RNAs: key players in glioblastoma drug resistance.Molecular and cellular biochemistry · 2021Review
- Integrative analysis identifies an immune-relevant epigenetic signature for prognostication of non-G-CIMP glioblastomas.Oncoimmunology · 2021Article
- Interaction Between Near-Infrared Radiation and Temozolomide in a Glioblastoma Multiform Cell Line: A Treatment Strategy?Cellular and molecular neurobiology · 2021Article
- Guiding Treatment Choices for Elderly Patients with Glioblastoma by a Comprehensive Geriatric Assessment.Current oncology reports · 2020Review
- Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.Clinical epigenetics · 2019Article
- The Clinical Significance of OFrontiers in neurology · 2018Article
- Glioblastoma Treatment in the Elderly.Neurologia medico-chirurgica · 2017Review
- Knockdown of Angiopoietin-Like Protein 2 Inhibits Proliferation and Invasion in Glioma Cells via Suppressing the ERK/MAPK Signaling Pathway.Oncology research · 2017Article
- Management of glioblastoma in elderly patients.Journal of the neurological sciences · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMany physicians are reluctant to treat elderly glioblastoma (GBM) patients as aggressively as younger patients, which is not evidence based due to the absence of validated data from primary studies. We conducted a meta-analysis to provide valid evidence for the use of the aggressive combination of radiotherapy (RT) and temozolomide (TMZ) in elderly GBM patients.
methodsA systematic literature search was conducted using the PubMed, EMBASE and Cochrane databases. Studies comparing combined RT/TMZ with RT alone in elderly patients (≥65 years) with newly diagnosed GBM were eligible for inclusion.
resultsNo eligible randomized trials were identified. Alternatively, a meta-analysis of nonrandomized studies (NRSs) was performed, with 16 studies eligible for overall survival (OS) analysis and nine for progression-free survival (PFS) analysis. Combined RT/TMZ was shown to reduce the risk of death and progression in elderly GBM patients compared with RT alone (OS hazard ratio [HR] 0.59, 95% confidence interval [CI] 0.48-0.72; PFS: HR 0.58, 95% CI 0.41-0.84). Evaluable patients were reported to tolerate combined treatment but certain toxicities, and especially hematological toxicities, were more frequently observed. Limited data on O6-methylguanine-DNA methyltransferase (MGMT) promoter status and quality of life were reported.
conclusionThe meta-analysis of NRSs provided level 2a evidence (Oxford Centre for Evidence-Based Medicine) that combined RT/TMZ conferred a clear survival benefit on a selection of elderly GBM patients who had a favorable prognosis (e.g., extensive resection, favorable KPS). Toxicities were more frequent but acceptable. Future randomized trials are warranted to justify a definitive conclusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.